Hoplite Pharmaceutical Holdings Limited (Hoplite Pharmaceuticals-B) submitted its monthly securities change report to Hong Kong Exchanges and Clearing Limited on September 4, 2024, covering the period up to August 31, 2024. The report shows that the company's registered capital and issued shares (excluding treasury shares) remained unchanged during this month, at 20,000,000,000 ordinary shares with a par value of $0.000025 per share, totaling $500,000; the total number of issued shares is 768,876,410 shares. In addition, within the company's stock option plan, 177,600 stock options expired this month, and no new shares were issued due to the exercise of options. The report also confirms that all securities issuances or sales of treasury shares during this month have been authorized by the board of directors and comply with all relevant listing rules and regulations.

Hoplite Pharmaceutical Holdings Limited (Hoplite Pharmaceuticals-B) submitted its monthly securities change report to Hong Kong Exchanges and Clearing Limited on September 4, 2024, covering the period up to August 31, 2024. The report shows that the company's registered capital and issued shares (excluding treasury shares) remained unchanged during this month, at 20,000,000,000 ordinary shares with a par value of $0.000025 per share, totaling $500,000; the total number of issued shares is 768,876,410 shares. In addition, within the company's stock option plan, 177,600 stock options expired this month, and no new shares were issued due to the exercise of options. The report also confirms that all securities issuances or sales of treasury shares during this month have been authorized by the board of directors and comply with all relevant listing rules and regulations.